Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN - Get Free Report) has earned an average rating of "Moderate Buy" from the twenty-seven analysts that are currently covering the stock, Marketbeat Ratings reports. Nine analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the

REGN wins FDA nod to extend Eylea HD dosing to 20 weeks, boosting flexibility for wAMD and DME patients while reinforcing its push to offset declining Eylea sales.

Regeneron (REGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sovran Advisors LLC reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 22.6% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,619 shares of the biopharmaceutical company's stock after selling 2,519 shares during the quarter. Sovran Advisors LLC's holdings in Regeneron

Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Regeneron hat die exklusive Möglichkeit, umfangreiche Genom- und Proteom-Datensätze mit dem branchenführenden globalen Netzwerk von TriNetX für elektronische

- TriNetX colabora con Regeneron para acceder a registros electrónicos de salud anonimizados de 300 millones de pacientes e impulsar la investigación y el

Aberdeen Group plc raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 6.8% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,738 shares of the biopharmaceutical company's stock after acquiring an additional 10,235

Regeneron a l'opportunité unique de connecter des cohortes de données génomiques et protéomiques à grande échelle au réseau mondial de données de dossiers

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data